PRME Medicine has just announced the publication of an important article in The New England Journal of Medicine. The article announces success in developing a new treatment using gene editing and stem cell therapy in clinical trials. The company has several additional drugs in development and it believes the methods and techniques they are developing will have applications across the medical spectrum. They are a startup-level business with proven success and multiple explosive possibilities in the pipeline. If any one of those creative gene-editing drugs proves successful this stock will skyrocket. it's a long-shot but in this case the upside looks better than the risk. Proceed at your own risk - with money you can live without.
How well do narratives help inform your perspective?
Disclaimer
The user RedhawkCC holds no position in NasdaqGM:PRME. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.